Institutional investors hold a majority ownership of BIIB through the 89.05% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2016, these large investors purchased a net $1.8 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 1.2 Million shares of Biogen
JENNISON ASSOCIATES LLC Bought 609.1 Thousand shares of Biogen
JPMORGAN INVESTMENT MANAGEMENT, ... Bought 497.5 Thousand shares of Biogen